Analysts Offer Predictions for Immunovant FY2028 Earnings

Immunovant, Inc. (NASDAQ:IMVT) – Research analysts at Zacks Research issued their FY2028 EPS estimates for Immunovant in a note issued to investors on Wednesday, June 18th. Zacks Research analyst E. Bagri anticipates that the company will earn ($2.81) per share for the year. The consensus estimate for Immunovant’s current full-year earnings is ($2.69) per share.

Immunovant (NASDAQ:IMVT) last posted its quarterly earnings data on Thursday, May 29th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.08. The firm had revenue of $0.16 million for the quarter. During the same quarter last year, the firm posted ($0.52) earnings per share.

Other equities analysts also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $51.00 price objective on shares of Immunovant in a report on Wednesday, March 19th. Cantor Fitzgerald upgraded shares of Immunovant to a “strong-buy” rating in a research note on Tuesday, March 4th. Jefferies Financial Group assumed coverage on shares of Immunovant in a research report on Monday, March 3rd. They set a “hold” rating and a $20.00 price target for the company. UBS Group restated a “neutral” rating and issued a $17.00 price objective (down previously from $38.00) on shares of Immunovant in a report on Tuesday, April 22nd. Finally, Bank of America lowered their target price on shares of Immunovant from $38.00 to $33.00 and set a “buy” rating for the company in a report on Thursday, March 20th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $38.33.

Immunovant Stock Down 2.1%

IMVT opened at $15.47 on Monday. Immunovant has a 52 week low of $12.72 and a 52 week high of $34.47. The stock has a market cap of $2.64 billion, a PE ratio of -5.65 and a beta of 0.61. The business has a 50 day moving average of $15.07 and a 200-day moving average of $19.09.

Insider Activity at Immunovant

In other news, CEO Peter Salzmann sold 28,094 shares of the company’s stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $12.99, for a total transaction of $364,941.06. Following the transaction, the chief executive officer now directly owns 1,186,512 shares of the company’s stock, valued at $15,412,790.88. This represents a 2.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CTO Jay S. Stout sold 1,925 shares of the stock in a transaction on Wednesday, April 23rd. The shares were sold at an average price of $14.79, for a total value of $28,470.75. Following the sale, the chief technology officer now directly owns 209,243 shares in the company, valued at $3,094,703.97. This trade represents a 0.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,682 shares of company stock valued at $596,619. 5.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Immunovant

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Immunovant by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 6,679,414 shares of the company’s stock valued at $165,449,000 after acquiring an additional 20,614 shares during the last quarter. Bank of America Corp DE boosted its holdings in Immunovant by 50.4% in the fourth quarter. Bank of America Corp DE now owns 341,535 shares of the company’s stock worth $8,460,000 after purchasing an additional 114,511 shares during the last quarter. Rhumbline Advisers grew its position in Immunovant by 1.5% in the 4th quarter. Rhumbline Advisers now owns 80,932 shares of the company’s stock worth $2,005,000 after purchasing an additional 1,188 shares during the period. Sei Investments Co. raised its stake in Immunovant by 4.0% during the 4th quarter. Sei Investments Co. now owns 40,456 shares of the company’s stock valued at $1,002,000 after buying an additional 1,541 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in Immunovant by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 28,063 shares of the company’s stock valued at $695,000 after buying an additional 9,349 shares during the last quarter. Hedge funds and other institutional investors own 47.08% of the company’s stock.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.